Nucleate

🚀 Nucleate Emerging Presents: Inside Business Development in Norway! Join us for our first Inside Series event, where we’ll dive into how to build a biotech company in Norway. We’ll discuss key challenges, opportunities, and insights from experts in the field. Speakers & Insights: ▪️Axel Zeiner from BIT Innovation Center – Our event host, sharing ways to support innovation. ▪️Shane West from Aleap – Introducing The Forge, Norway's first national biotechnology accelerator. ▪️Ernest Aw from Thelper AS – Discussing the intersection of business and scientific development for biotech startups in Norway. ▪️Markus Dietrich, PhD from Hadean Ventures – Providing insights from a VC perspective on biotech funding and growth. If you're eager to learn more about Norwegian biotech and network with the local biotech community, join us on Monday, 24th February! Date & Time: 24th February, 16:30 Location: BIT Innovasjonssenter (Storsalen, Conference Room R139), NMBU RSVP: https://lu.ma/ma19926g

🚀 Exciting news from Nucleate! Pillar VC and Amino Collective have joined as dedicated partners for the 2025 Nucleate Venture Fellowship, bringing their expertise to support the next generation of biotech innovators. The Nucleate Venture Fellowship is a 16-week program designed for graduate trainees in life sciences and medicine, offering hands-on experience in biotech investment. Fellows will conduct due diligence on groundbreaking startups, collaborate with top investors, and receive one-on-one mentorship to accelerate their careers in venture capital. Through this partnership: ✅ Pillar VC extends its four-year collaboration, providing mentorship and funding for select Activator teams. ✅ Amino Collective joins as a new partner, strengthening support for bold biotech founders worldwide. Applications for the 2025 Nucleate Venture Fellowship are now open! If you're a graduate trainee passionate about biotech and venture capital, this is your chance to gain real-world experience, build your network, and access a fully virtual, stipend-supported program. Learn more about this opportunity here: https://lnkd.in/gzrm3U_7 Apply by March 7th: https://lnkd.in/g9rtHD3g

Join us this Friday, February 21st for the first event of our inaugural Inside Global Life Sciences series! Register here: https://lnkd.in/gXMp8xqt We are excited to feature speakers Andy Boyce and Markus Herrgård, representing Norway and Denmark respectively. 🇳🇴 Andy Boyce, Senior Advisor at Innovation Digital Life Norway manages the Norwegian Research Council-funded Innovation Roadmap project with a 30M NOK budget aimed at transforming Norway’s biotech ecosystem. Having founded a University of Bristol spinout, Andy brings deep expertise in commercializing biotech innovations and is driving forward a strategic roadmap for research-intensive biotechnology. 🇩🇰 Markus Herrgård, CTO at the BioInnovation Institute in Copenhagen, is shaping the institute's science and technology strategy. He oversees an incubator that supports over 70 startups tackling human and planetary health challenges. With a background in quantum engineering and bioengineering, along with pivotal roles at Synthetic Genomics and the Novo Nordisk Foundation Center for Biosustainability, Markus is at the forefront of biotechnological solutions for sustainability.

Join us for our third Tech Talk with Joel Shor, former VP of Machine Learning at Deep Genomics and now a techbio consultant at Move37 Labs. Discover how his team—working with researchers from MIT and Google—is pushing the boundaries of AI-driven nucleic acid sequence design to engineer superior therapeutics. Wednesday, February 19th, 2pm PST, on zoom. Register: https://lnkd.in/gzWivg2A About the series: Nucleate’s AIxBio Tech Talks provide real world insight into how AI is transforming biotech. In each session, attendees will hear from a leading practitioner in AIxBio about their vision and technical approach, followed by an audience Q&A.

Today’s the day! Junevity today is officially announcing our first $10 million of Seed VC funding to develop cell reset therapeutics for longevity. We’re on a mission to extend lifespan and healthspan by resetting cell damage from age-related diseases. Founded out of UCSF in 2023, Junevity’s RESET platform is the first to use large-scale human data and AI to identify novel transcription factor targets and repress them with siRNA. The initial focus is Type 2 diabetes, obesity and frailty, with the potential to address numerous longevity and aging-related indications. We thank Adam Ross and Daniel Friedland at Goldcrest Capital and Jason Godfrey at Godfrey Capital for their lead investment, support and partnership. Read more about our funding here: https://lnkd.in/gJbJWU5U Coverage by Longevity.Technology: https://lnkd.in/eJgnUwuD Coverage by Endpoints News: https://lnkd.in/g_rqbXpM

Junevity Raises $10M to Develop Cell Reset Therapeutics for Longevity! Founded by a team of experts in aging biology, machine learning and drug development and based on pioneering research for resetting cell health by Dr. Janine Sengstack of UCSF. Junevity’s RESET platform uses large-scale human data and AI to identify novel transcription factor targets and repress them with siRNA. The initial focus is Type 2 diabetes, obesity and frailty, with the potential to address numerous indications. Congratulations to Dr. Janine Sengstack (the one in the middle), the UCSF founder. Read: https://lnkd.in/gJbJWU5U

Join Us for the Second Inside Fundraising Seminar – Exploring Alternatives to Venture Capital! Looking for funding beyond traditional venture capital? Discover the potential of philanthropic and angel investing in the next session of our Inside Fundraising Series. We’re featuring two experienced investors who will share their insights: ▫️ Lili Clark, Senior Associate at Lyda Hill Philanthropies/Lyda Hill Capital Inc. ▫️ Zack Storms, Co-founder at TNT Startups They’ll discuss their companies’ current investment criteria, how to connect with them, and best practices for communicating with these funding sources. Don’t miss this chance to explore alternative funding opportunities and gain expert insights! Register here: https://lu.ma/qzqjyxlu

Join us for a pivotal conversation on the future of aging therapeutics! On March 3, 2025, we’re continuing Nucleate: Inside Aging with an insightful virtual session featuring leaders in aging biology and therapeutics: 🎙 Nir Barzilai, MD Founder and Director, Institute for Aging Research 🎙 Joan Mannick, MD CEO & Co-Founder, Tornado Therapeutics 🎙 Matt Kaeberlein, Ph.D. CEO, Optispan, Inc. These renowned experts will share their vision on the path from aging therapeutics research to clinical applications and how you can get involved in the field’s groundbreaking work. This is a must-attend event for: ▫️ Researchers and students passionate about aging therapeutics. ▫️ Investors exploring innovative aging biotech. ▫️Anyone eager to understand how science is transforming aging and health. 💡 Don’t miss out—register today: https://lnkd.in/gbfend-E 💡 1pm ET Let’s innovate and shape the future of aging therapeutics together! #AgingTherapeutics #AgingBiology #Longevity #NucleateInsideAging #Innovation #Biotechnology #VirtualEvent

Join us this Wednesday, February 12th, for the Next Inside Business Development Seminar! This seminar will focus on developing your commercialization strategy and the key factors to consider during the early-stage company formation process. We’re excited to feature two accomplished entrepreneurs: ▫️ Erwin Estigarribia, CEO of Headlamp Health ▫️ Celina Burns, Co-founder & CEO of Unifyed Health They’ll share firsthand insights on successfully launching and scaling companies in a moderated Q&A, followed by an open floor discussion where you can ask your burning questions. Don't miss this opportunity to learn from industry leaders and connect with like-minded professionals! RSVP here: https://lu.ma/5cd9xlsi

🚀 Revolutionizing Gene Therapy with AI-Powered Capsid Engineering What happens when you combine physics, systems biology, and machine learning to tackle one of the biggest challenges in gene therapy? You get Dyno Therapeutics—a company pioneering AI-driven capsid engineering to improve gene delivery and make therapies more effective and accessible. In this latest episode with Sam Kessel MD, MBA, Eric Kelsic, CEO and co-founder of Dyno, shares his journey: 🔬 How his physics and systems biology background shaped his approach to solving biological problems 🧬 Lessons learned from working in George Church’s lab at Harvard 🤖 How Dyno uses machine learning to engineer better AAV capsids 🤝 Using the scientific method to approach business development Kelsic’s story is a masterclass in identifying high-impact problems, leveraging cutting-edge technology, and translating scientific insights into therapeutics to improve patient’s lives. Check out the full episode to dive into the future of AI-powered gene therapy! 🎧👇 https://lnkd.in/gt6TDTZY #GeneTherapy #AI #Biotech #Innovation #MachineLearning